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Imbalances in glucose and energy homeostasis are
at the core of the worldwide epidemic of obesity
and diabetes. Here, we illustrate an important role
of the TGF-b/Smad3 signaling pathway in regulating
glucose and energy homeostasis. Smad3-deficient
mice are protected from diet-induced obesity and
diabetes. Interestingly, the metabolic protection is
accompanied by Smad3/ white adipose tissue
acquiring the bioenergetic and gene expression
profile of brown fat/skeletal muscle. Smad3/
adipocytes demonstrate a marked increase in mito-
chondrial biogenesis, with a corresponding increase
in basal respiration, and Smad3 acts as a repressor
of PGC-1a expression. We observe significant corre-
lation between TGF-b1 levels and adiposity in
rodents and humans. Further, systemic blockade of
TGF-b signaling protects mice from obesity, dia-
betes, and hepatic steatosis. Together, these results
demonstrate that TGF-b signaling regulates glucose
tolerance and energy homeostasis and suggest that
modulation of TGF-b activity might be an effective
treatment strategy for obesity and diabetes.
INTRODUCTION
Positive energy balance ensues when energy intake exceeds
energy expenditure, leading to net storage of excess calories
in the form of fat in the adipose tissue. Mammalian adipose
tissue is broadly classified as either white adipose tissue (WAT)
or brown adipose tissue (BAT). WAT functions as an energy
storage depot characterized by large lipid droplets and is a prom-
inent endocrine organ, producing hormones that regulatefeeding and satiety (Rosen and Spiegelman, 2006). In contrast,
BAT is an energy dissipation depot characterized by densely
packed mitochondria and unique expression of uncoupling
protein-1 (UCP1) (Cannon and Nedergaard, 2004, 2011). Inter-
estingly, three distinct tissues—the dermis, muscle, and brown
fat—originate from the central dermomyotome (Atit et al.,
2006). Immature undifferentiated brown fat cells harbor
muscle-specific transcripts, and microarray analyses revealed
that brown preadipocytes exhibit a myogenic transcriptional
signature (Timmons et al., 2007). Intrascapular BAT appears
developmentally related to skeletal muscle, with both tissues
harboring abundant mitochondria, and the transcription factor
PRDM16 determines the fate of precursor cells toward brown
fat cells (Seale et al., 2008, 2009). Recent findings that metabol-
ically active BAT stores exist in humans (Nedergaard et al., 2007)
have stimulated interest concerning the therapeutic potential of
augmenting BAT to combat metabolic diseases (Enerba¨ck,
2010; Nedergaard and Cannon, 2010).
Interestingly, brown adipocytes are also observed inter-
spersed within WAT in response to cold exposure or upon stim-
ulation by b-adrenergic pathways (Cousin et al., 1992; Guerra
et al., 1998). However, intrascapular BAT and brown adipocytes
interspersed within the WAT may have distinct origins, and their
development may be regulated by different genetic programs
(Xue et al., 2007). Accumulating evidence has prompted the
classification of adipocytes into three subtypes: the brown
adipocyte, the white adipocyte, and the brown adipocytes in
WAT (Petrovic et al., 2010). Identification of signaling pathways
that regulate acquisition of BAT properties by WAT could foster
development of novel therapies for obesity and T2D.
TGF-b and its related factors control the development, growth,
and function of diverse cell types (Shi and Massague´, 2003).
TGF-b transmits its signals via dual serine/threonine kinase
receptors and transcription factors called Smads, with Smad3
serving as the principal facilitator of TGF-b signals (Feng and
Derynck, 2005). TGF-b levels correlate with obesity in mice
(Samad et al., 1997, 1999) and humans (Alessi et al., 2000;Cell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc. 67
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Figure 1. Smad3 Loss Protects against Diet-Induced Obesity, Insulin Resistance, and Hepatic Steatosis
(A–C) Increased glucose infusion rate (A), whole-body glucose uptake (B), and WAT glucose uptake (C) in Smad3/mice (KO), compared with Smad3+/+ mice
(WT).
(D–F) Lower-body weight gain (D), improved glucose (E) and insulin (F) tolerance in KOmice fed either a regular diet (RD; open red symbols) or high-fat diet (HFD;
closed red symbols) compared to WT mice fed a RD (open black symbols) or HFD (closed black symbols).
(G and H) HFD-fed KO mice showed significantly lower glucose (G) and insulin (H) levels compared to WT mice fed a HFD.
(I) Enhanced insulin receptor signaling activity in Smad3/ WAT.
(J) HFD-fed Smad3/ mice, but not HFD-fed Smad3+/+ mice, are resistant to hepatic steatosis. *p < 0.05; **p < 0.005; ***p < 0.001.
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TGF-b/Smad3 Signaling in Diabetes and ObesityFain et al., 2005; Lin et al., 2009b). We recently described an
important role of the TGF-b/Smad3 pathway in regulation of
insulin gene transcription and b cell function (Lin et al., 2009a).
However, the importance of TGF-b signaling in energy homeo-
stasis and pathogenesis of diabetes and obesity is largely
obscure and a focus of this study.
RESULTS
Smad3 Loss Protects against Diet-Induced Obesity
and Insulin Resistance
During a hyperinsulinemic-euglycemic clamp experiment,
Smad3/ mice exhibit enhanced insulin sensitivity, as evi-68 Cell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc.denced by elevated glucose infusion rate (Figure 1A) and
increased whole-body glucose uptake (Figure 1B). Increased
glucose uptake was particularly marked in WAT (Figure 1C) as
opposed to other metabolically active tissues, such as skeletal
muscle (data not shown). When challenged with high-fat diet
(HFD), Smad3/ mice gained less weight (Figure 1D) and
exhibited enhanced glucose tolerance (Figure 1E) and insulin
sensitivity (Figure 1F), leading to lower fasting blood glucose
and insulin levels (Figures 1G and 1H). Further, we observed
increased activation of the insulin receptor signaling pathway
in Smad3/ WAT (Figure 1I). HFD-fed Smad3+/+ mice devel-
oped hepatic steatosis, a condition frequently observed during
insulin resistance, characterized by ectopic fat deposition in liver
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Figure 2. Smad3 Deficiency Suppresses White Adipose Tissue Differentiation
(A) WT and KO mice intake similar caloric energy, as monitored by weekly food intake.
(B and C) RD-fed or HFD-fed KO mice harbor reduced fat mass (B) and triglyceride levels (C).
(D and E) KO adipocytes (red) on a RD (open symbols) or HFD (closed symbols) maintain smaller size compared to WT adipocytes (black).
(F and G) KO mice fed RD or HFD exhibit significantly reduced levels of inflammatory M1 macrophage-specific transcripts (F) and increased levels of protective
M2 macrophage-specific transcripts (G). *p < 0.05; **p < 0.005; ***p < 0.001.
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TGF-b/Smad3 Signaling in Diabetes and Obesitytissue (Figure 1J). Remarkably, HFD-fed Smad3/ mice were
protected from hepatic steatosis (Figure 1J). These results illus-
trate that Smad3 deficiency confers enhanced insulin sensitivity
and prevents HFD-induced obesity, insulin resistance, and
hepatic steatosis.
Smad3 Loss Induces WAT to BAT Phenotypic Transition
The observed differences in body weight between wild-type and
Smad3/mice were not due to differences in caloric intake (Fig-
ure 2A). Interestingly, Smad3/ mice display significantly
reduced fat mass (Figure 2B), which, taken together with the
enhanced glucose uptake in the WAT (Figure 1C), prompted
examination of the WAT compartment in greater detail.
Smad3/MEFs were markedly impaired in their ability to differ-
entiate into white adipocytes (Figure S1A). Consistent with these
results, we also observed reduced expression of white adipo-
cyte-specific genes in Smad3/ MEFs (data not shown) and in
Smad3/ WAT (Figure S1B). Furthermore, WAT-derived (Fig-
ure S1D) and circulating levels of triglyceride (Figure 2C),
leptin, and resistin (Figures S1E and S1F) were significantly
reduced in Smad3/ mice. Immunofluorescence staining for
the WAT-specific protein, perilipin, revealed reduced adipocyte
size in Smad3/ WAT (Figures 2D, 2E, and S1C). Smad3/
mice also exhibited reduced levels of inflammatory cytokinesand less inflammatory macrophage infiltration into WAT, with
a switch in macrophage spectrum from inflammatory M1 to
protective M2 macrophages (Lumeng et al., 2007) (Figures 2F,
2G, and S1G–S1J).
The observed reduction in fat mass (Figure 2B) and the overall
smaller adipocyte size (Figures 2D and 2E) led us to postulate
that Smad3/ WAT may harbor features that promote energy
dissipation. As expected, Smad3+/+ WAT appeared pale white
in color and comprised predominantly large unilocular adipo-
cytes (Figure 3A). In contrast, Smad3/ WAT possessed
a dark-red color and was comprised of smaller and multilocular
adipocytes interspersed within the milieu of larger unilocular
white adipocytes (Figure 3A)—a morphology that resembled
brown adipocytes (Cousin et al., 1992). Consistent with this
notion, we observed that many cells in the Smad3/ WAT
stained positive for UCP1 (Figure 3B), a marker uniquely present
in brown adipocytes. In contrast, UCP1+ cells were absent in
Smad3+/+ WAT. Further, we observed increased mRNA expres-
sion of markers of brown adipogenesis (Seale et al., 2009), i.e.,
PGC-1a, UCP1, and PRDM16 in Smad3/ WAT (Figure 3C),
andUCP1 protein level was also increased (Figure 3D). To further
characterize the role of Smad3, we established a 3T3-L1 preadi-
pocyte cell-based system where Smad3 expression was
knocked down using a lentivirus expressing short hairpin RNACell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc. 69
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Figure 3. Smad3 Loss Induces White Fat to Brown Fat Phenotypic Transition
(A) RD-fed or HFD-fed Smad3/ mice harbor reduced fat mass and smaller adipocytes.
(B) UCP1 expression in KO WAT (arrows).
(C) KO WAT displays enhanced expression of BAT-specific genes.
(D) KO WAT displays increased expression of BAT/mitochondrial-specific proteins and reduced expression of WAT-specific proteins.
(E and F) KO mice exhibit significant elevation in body temperature during day and night (active) conditions (E) and defend against extended cold exposure (F).
(G) KO mice exhibit enhanced fatty acid oxidation in their primary adipocytes. *p < 0.05; **p < 0.005; ***p < 0.001.
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TGF-b/Smad3 Signaling in Diabetes and Obesityagainst Smad3 (shSmad3). Upon treatment with white adipocyte
differentiation medium, 3T3-L1 cells expressing shSmad3
showed elevated mRNA and protein expression of BAT-specific
markers (PGC-1a, UCP1, Cidea), as compared to 3T3-L1 cells
infected with a control lentivirus (Figures S2A and S2B).
Together, these results emphasize that loss of Smad3 signal
promotes acquisition of brown adipocyte features in white
adipocytes.
UCP1 andPGC-1a typically are activated in the BAT upon cold
exposure (Cannon and Nedergaard, 2004). To compare the rela-
tive expression of these genes in WAT and BAT, we performed
real-time RT-PCR analyses using basal and cold-activated
BAT and WAT tissue from Smad3/ and Smad3+/+ mice. We
observed significantly elevated gene expression of BAT-specific
genes in Smad3/ epididymal WAT, both in basal and cold-
exposure conditions (Table S1). Moreover, protein levels of
BAT-specific markers were significantly increased in Smad3/
WAT (Figure 3D). As expected, the degree of expression of
BAT-specific markers was higher in the intrascapular BAT
compared to that observed in WAT (Figure 3D). Taken together,
these observations are consistent with an active brown adipo-
genesis program in Smad3/ WAT. The protein expression of70 Cell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc.brown adipocyte markers, although higher than that seen in
WAT, was similar in the Smad3/ and Smad3+/+ BAT both
during basal and cold-exposure conditions (Figure 3D).
However, we observed a significant increase in BAT-specific
transcripts in cold-activated Smad3/ BAT, compared to
cold-activated Smad3+/+ BAT (Table S1). Taken together, we
suggest that Smad3 loss promotes acquisition of brown fat
features in the white fat.
We next inquired whether the occurrence of brown adipocytes
in the WAT was of physiological relevance. Smad3/ mice
exhibit higher basal body temperature during day and night
(active) conditions (Figure 3E). Moreover, Smad3/ mice were
able to maintain significantly higher body temperature when
exposed to cold for an extended time (Figure 3F). Interestingly,
we also observed significantly elevated fatty acid oxidation in
Smad3/ adipocytes (Figure 3G).
Smad3 Loss Promotes Mitochondrial Biogenesis
and Function in WAT
Brown adipocytes, akin to skeletal muscle cells, demonstrate
abundant mitochondria. Our data demonstrate that Smad3/
WAT exhibits increased expression of PGC-1a, the master
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Figure 4. Smad3 Loss Promotes Mitochondrial Biogenesis and Function in WAT
(A) MitoTracker green fluorescence in adipocytes and electron microscopy in WAT mitochondria (Mito-EM).
(B and C) KO adipocytes exhibit significantly elevated citrate synthase activity (B) and ATP content (C).
(D) Representative oxygen consumption by mitochondria isolated from WAT in the presence of pyruvate/malate, ADP, and the inhibitors oligomycin and
actractyloside. The oxygen consumption rate (nmol/min/mg prot) is shown below the trace after the addition of the mentioned substrates and inhibitors.
(E) KO primary adipocytes exhibit significantly increased oxygen consumption. The fold differences in oxygen consumption are derived from the calculated slope
of oxygen utilization.
(F) Respiratory control ratio (RCR) (State3/State4) of isolated WAT mitochondria demonstrating increased mitochondrial uncoupling, as evidenced by a lower
RCR, in KO tissue (n = 4 separate mitochondrial preparations per genotype).
(G) Oxygen consumption rate (OCR) is increased in intact shSmad3 lentivirus-infected 3T3-L1 cells in basal conditions and further enhanced by the addition of
1 mMnorepinephrine (NE). NE does not affect OCR in control cells. The addition of complex III inhibitor antimycin A (AA) inhibits respiration in both cells. For basal
OCR versus OCR after NE addition, control versus ShSmad3 is p < 0.001 for all measurements.
(H and I) Resting oxygen consumption at 20C (H) and respiratory exchange ratio (I) in 3-month-old female Smad3+/+ (WT) and Smad3/ (KO) mice fed chow diet.
*p < 0.05; **p < 0.005; ***p < 0.001.
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TGF-b/Smad3 Signaling in Diabetes and Obesityregulator of mitochondrial biogenesis. To understand the func-
tional importance of this augmented expression, we next sought
to assess mitochondrial number and activity in Smad3/ WAT.
Consistent with the observed increase in PGC-1a, Smad3/
WAT exhibited increased staining of the mitochondria-specific
fluorophore Mito-Tracker Green (Figure 4A) and increased mito-
chondrial DNA copy number (Figure S3A). Furthermore, morpho-
logical evaluationbyelectronmicroscopyofmitochondriaderived
from Smad3/ WAT revealed organelles with densely packed
cristae (Figure 4A), a feature characteristic of brown adipocyte
mitochondria (Cousin et al., 1992). Further, Smad3/ WAT ex-
hibited elevated citrate synthase activity (Figure 4B), consistentwith enhanced mitochondrial content or function. We also
observed an increase in basal ATP content (Figure 4C). In
addition, we observed significantly increased expression of mito-
chondrial-specific transcripts inSmad3/WAT, under basal and
cold-exposure conditions (Table S1 and Figure S3D). This
phenomenon appeared cell autonomous since 3T3-L1 cells ex-
pressing shSmad3 showed elevated gene expression of mito-
chondrial specificmarkers (Figure S3E). Finally, we also observed
elevated protein expression of multiple essential mitochondrial
gene products (Wilson-Fritch et al., 2004), ATP synthase, and
cytochrome oxidase in 3T3-L1 cells expressing shSmad3 lenti-
virus and in Smad3/WAT (Figures S2B and S2C).Cell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc. 71
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TGF-b/Smad3 Signaling in Diabetes and ObesityEvaluation of isolated mitochondria from WAT of Smad3+/+ or
Smad3/ mice demonstrated that in the presence of the
Complex I-dependent substrates pyruvate/malate, Smad3/
mitochondria had increased rates of basal respiration (Figure 4D
and Table S2). This observation was consistent with the
observed increase in the basal rate of oxygen consumption in
intact Smad3/ primary adipocytes (Figure 4E). Although basal
rates of respiration were lower in Smad3+/+ mitochondria,
following addition of ADP, the oxygen consumption rate (state
3 respiration) increased by approximately 4-fold (Figure 4D and
Table S2). In contrast, consistent with increased uncoupling in
the isolated mitochondria, less than a 2-fold increase in oxygen
consumption rate was observed following ADP addition to the
Smad3/ mitochondria. Addition of oligomycin and atractylo-
side, agents that block proton conductance through the ATP
synthase and adenine nucleotide translocator, respectively, in-
hibited oxygen consumption in Smad3+/+ mitochondria but not
in mitochondria derived from Smad3/mice. However, consis-
tent with increased uncoupling of the isolated mitochondria, oli-
gomycin-resistant respiration in WAT mitochondria from
Smad3/ mice was effectively inhibited by the addition of
GDP (Shabalina et al., 2004), a known inhibitor of UCP1 (Fig-
ure S4B). These results were also supported by a marked differ-
ence in the respiratory control ratio (Figure 4F) between
Smad3+/+ and Smad3/ mitochondria. Finally, in support of
the notion that deletion of Smad3 results in a brown fat bioener-
getic phenotype, we noted that when compared to control
infected cells, 3T3 L1 cells expressing shSmad3 exhibited higher
basal oxygen consumption (Figures 4G and S4A), presumably
due to increasedmitochondrial number. In shSmad3 cells, respi-
ration could be further augmented by the addition of norepineph-
rine (Figure 4G), a potent activator of UCP1 activity in brown fat
(Matthias et al., 2000). Smad3/ mice also showed increased
metabolic rate, adjusted to lean mass or to total body weight,
both at 20C and at 30C (Figures 4H and S4D–S4F). Further,
Smad3/ mice exhibited lower respiratory exchange ratio
(RER) (Figure 4I), in agreement with the observed increase in
mitochondrial function and lipid oxidation (Figure 3G).
Ablation of TGF-b/Smad3 Signal Induces BAT/Skeletal
Muscle Signature in WAT
To comprehensively delineate TGF-b/Smad3-regulated tran-
scriptional targets that control acquisition of brown fat features
by WAT, we performed microarray analyses of WAT isolated
from Smad3+/+ and Smad3/ mice fed either RD or HFD. In
addition, we performed microarray analyses of WAT from diet-
induced obese (DIO) mice treated with an anti-TGF-b neutraliza-
tion antibody (1D11) or with the isotype control 13C4 antibody
(IgG). Interestingly, unsupervised cluster analyses showed that
WAT from Smad3/ mice and from mice treated with 1D11
exhibit highly significant increases in transcripts that correspond
to BAT, mitochondrial function, and skeletal muscle biology (Fig-
ure 5A). Moreover, hierarchical clustering revealed a ‘‘signature’’
of 103 genes that predominantly include regulators of BAT/mito-
chondria (such as PGC-1a, Ucp1, Dio2, Cidea, and cytochrome
c oxidase) and skeletal muscle biology (such as myosin,
troponin, and tropomyosin) (Figure 5B and Table S3). These
results demonstrate that suppression of TGF-b/Smad3 signaling
promotes the acquisition of a BAT/skeletal muscle phenotype in72 Cell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc.WAT. Furthermore, we observed significantly increased expres-
sion of skeletal muscle-specific genes in basal and cold-acti-
vated Smad3/ WAT (Table S1). Together, these observations
are consistent with the link between brown fat and skeletal
muscle (Seale et al., 2008).
PGC-1a is a transcriptional coactivator that regulates genes
involved in energy metabolism and provides a direct link
between external physiological circuits and the regulation of
mitochondrial biogenesis (Lin et al., 2005). TGF-b target genes
are regulated by binding of Smad3 to Smad-binding elements
(SBEs) on gene promoters (Feng and Derynck, 2005), and
sequence analysis revealed the presence of SBEs on the
PGC-1a promoter. Chromatin immunoprecipitation (ChIP)
assays showed evidence of Smad3 binding to the PGC-1a
promoter in 3T3-L1 cells (Figure 5C). Furthermore, TGF-b sup-
pressed the PGC-1a luciferase reporter in 3T3-L1 cells, whereas
TGF-b was unable to repress the promoter in 3T3-L1 cells ex-
pressing shSmad3 (Figure 5D), indicating that TGF-b represses
the PGC-1a promoter in a Smad3-dependent manner.
We next developed a 3T3-L1 cell-based system where, via
lentivirus-based shRNA technology, we could reduce expres-
sion of Smad3 and PRDM16 either individually or in combination
and analyze the resultant effects on BAT andWAT-specific gene
expression. As expected, knockdown of PRDM16 repressed
expression of BAT-specific genes, while the levels of WAT-
specific genes were elevated (Figure 5E). In contrast, Smad3
knockdown resulted in upregulation of BAT-specific genes and
repression of the WAT-specific genes (Figure 5E). Interestingly,
knockdown of Smad3 and PRDM16 together yielded an interme-
diate phenotype wherein the effects of Smad3 in repressing
BAT-specific gene expression or that of PRDM16 in promoting
BAT-specific gene expression were effectively neutralized (Fig-
ure 5E). Together, these results support the notion of Smad3
regulating the appearance of brown-like adipocytes in the WAT
by regulating the PGC-1a-PRDM16 axis (Figure 5F).
TGF-b1 Levels Positively Correlate with Adiposity,
and Exogenous TGF-b1 Represses BAT/Mitochondrial
Genes
While the findings thus far supported the concept that reduced
TGF-b/Smad3 signals are beneficial to glucose and energy
homeostasis, they also suggested that elevated TGF-b levels
might promote glucose intolerance and obesity. We examined
circulating TGF-b1 levels in a total of 184 nondiabetic human
subjects of diverse ethnic origin derived from two studies:
Study I exclusively included blacks of African American descent
(Sumner et al., 2005), and Study 2 included subjects of
diverse ethnic origin (Caucasian, Black, Hispanic, and Asian)
(Table S4). Subjects had normal liver function tests and were
primarily devoid of liver fibrosis and fatty liver disease. TGF-b1
levels were similar between men and women (p = 0.079) and
between black subjects and nonblack subjects (p = 0.75).
Circulating TGF-b1 levels were not correlated with age (r =
0.07, p = 0.32). Significant correlations between TGF-b1 levels
and BMI, fat mass, and VO2 consumption in the subjects sug-
gested that elevated TGF-b1 levels associate with poor meta-
bolic profile in human subjects (Table S4). After adjusting for
age and fasting insulin level, the partial correlation between
BMI and TGF-b1 was statistically significant (Figure 6A;
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Figure 5. Smad3 Regulates the PGC-1a Promoter and PRDM16 Target Genes
(A) Representative heat map of microarray analyses of WAT from RD- or HFD-fed WT and KO mice and from diet-induced obese (DIO) mice treated with control
IgG or anti-TGF-b (a-TGF-b) antibody.
(B) Pie-chart classification of ‘‘103 signature genes’’ (represented in the three boxed areas of the heat map) in WAT from RD- or HFD-fed KO mice and from DIO
mice treated with a-TGF-b antibody, compared to RD- or HFD-fed WT mice and from DIO mice treated with control IgG, respectively.
(C) ChIP assays show binding of Smad3 (arrowhead) to the PGC-1a promoter in 3T3-L1 cells. Input and IgG antibody control is shown.
(D) TGF-b suppresses the PGC-1a-luciferase reporter in 3T3-L1 cells, but not in 3T3-L1 cells expressing shSmad3 lentivirus.
(E) Smad3 regulates PRDM16 target genes. Control 3T3-L1 cells were infectedwith lentiviruses expressing GFP (3T3-L1GFP), shPRDM16 (3T3-L1 + shPRDM16),
shSmad3 (shSmad3 +GFP), or shSmad3 and ShPRDM16 together (shSmad3 + shPRDM16), followed by real-time RT-PCR. Fold change in expression relative to
18S is shown.
(F) Proposed model for WAT to BAT phenotypic conversion upon loss of Smad3 signaling. Loss of Smad3 leads to enhanced expression of BAT/mitochondrial/
muscle-specific transcripts along with reduced expression ofWAT-specific genes. The appearance of UCP1+ brown adipocytes in theWATmilieu is promoted by
PRDM16. *p < 0.05; **p < 0.005; ***p < 0.001.
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TGF-b/Smad3 Signaling in Diabetes and Obesityr = 0.287, p < 0.001). Moreover, as shown in Figure 6B, TGF-b1
levels proportionately increased with adiposity in overweight
(BMI of 25–29.9 kg/m2) and obese (BMI of >30 kg/m2) subjects
compared to normal subjects (BMI of <24.9 kg/m2). In addition,
we observed inverse correlation of TGF-b1 levels with VO2 max
(Figure S5A; r = 231, p = 0.009). Together, these results show
a significant positive association between TGF-b1 and human
adiposity. In addition, positive correlations were observed with
fat mass, fasting insulin levels, and HOMA insulin resistanceindex, but not with blood pressure (DBP) and levels of fasting
glucose, triglyceride, free fatty acids, and insulin sensitivity (SI)
(Figures S5B–S5I).
We next examined TGF-b1 levels in Lepob/ob and DIO mouse
models as a function of their adiposity and diabetes. Circulating
TGF-b1 levels were measured in Lepob/ob mice starting at
4 weeks age (body weight 25 ± 1.3 g) until the mice doubled their
body weight (53 ± 3.2 g) and exhibited insulin resistance and dia-
betes. Elevated TGF-b1 levels were observed as Lepob/ob miceCell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc. 73
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Figure 6. Elevated TGF-b1 Level Correlates with Adiposity and Exogenous TGF-b1 Suppresses BAT/Mitochondrial Markers in WAT
(A and B) Plasma TGF-b1 levels in human subjects significantly correlate positively with BM1 (A), and increased TGF-b1 levels are seen in overweight and obese
subjects, compared to that seen in subjects with normal BMI (B).
(C and D) Levels of active TGF-b1 were determined by ELISA in serum samples from Lepob/ob mice as a function of their weight gain (C) and in C57BL/6Jmice fed
either a RD (control) or HFD for 8 weeks (D).
(E) Elevated active TGF-b1 (green) staining in perilipin (red) expressing white adipocytes in WAT from Lepob/ob and DIO mice, but not in WAT derived from regular
diet-fed normal mice (Control). DAPI staining identifies nuclei.
(F) Elevated phosphorylated Smad3 in WAT protein extracts from Lepob/ob (n = 4) and DIO (n = 4) mice, but not in WAT derived from regular diet-fed normal mice
(Con; n = 3). Total Smad3 levels are shown in the bottom panel.
(G–I) Compared to vehicle PBS-injected mice (open bars), mice injected with TGF-b1 (closed red bars) exhibit elevated WAT-specific transcripts (G) and reduced
BAT-specific (H) and mitochondrial-specific transcripts (I). *p < 0.05; **p < 0.005; ***p < 0.001.
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levels occurred with a doubling of the body weight of these mice
(Figure 6C). TGF-b1 levels were also measured in normal wild-
type mice fed a regular diet (RD) or HFD for 10 weeks. Increased
body weight and insulin resistance in the HFD-fed mice was
accompanied by a significant 5- to 7-fold increase in TGF-b1
levels compared to mice fed a RD for 10 weeks (Figure 6D).
Moreover, elevated active TGF-b1 immunoreactivity was seen
in perilipin-positive adipocytes in the WAT from Lepob/ob and
DIO mice (Figure 6E). Also, we observed increased levels of74 Cell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc.phosphorylated Smad3 inWAT from Lepob/ob and DIOmice (Fig-
ure 6F). Interestingly, intraperitoneal injection of TGF-b1 in
normal mice resulted in elevated WAT-specific transcripts (Fig-
ure 6G), whereas the expression of BAT/mitochondrial tran-
scripts was significantly suppressed (Figures 6H and 6I).
Anti-TGF-b Antibody Protects Lepob/ob and DIO Mice
from Obesity and Diabetes
The studies thus far indicated a beneficial effect of suppressing
TGF-b/Smad3 signals on glucose tolerance, body weight gain,
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Figure 7. Anti-TGF-b Antibody Protects Lepob/ob and DIO Mice from Obesity and Diabetes
(A) Reduced phosphorylated Smad3 in WAT protein extracts from Lepob/ob (n = 3) and DIO (n = 3) mice treated with anti-TGF-b (a-TGF-b) antibody.
(B–H) Treatment with anti-TGF-b (a-TGF-b) antibody resulted in significantly reduced bodyweight gain, improvedGTT (C), enhanced ITT (D), significantly reduced
fasting blood glucose (E) and fasting insulin levels (F), suppression of hepatic steatosis (G), and elevated expression of BAT/mitochondrial-specific proteins in
WAT (H). *p < 0.05; **p < 0.005; ***p < 0.001.
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of these findings, we evaluated the effects of the anti-TGF-
b neutralization antibody (1D11) in twowell-characterizedmouse
models of obesity and T2D. The efficacy of 1D11 (a-TGF-b) has
been tested in preclinical disease models (Ling et al., 2003; Nam
et al., 2008), and a closely related human version of this antibody,
designated Fresolimumab, is currently being tested in human
clinical studies of pulmonary fibrosis, renal disease, and cancer.
We evaluated the effects of 1D11 in (1) Lepob/ob mice that
develop obesity and insulin resistance due to deficient leptin
signaling and (2) a DIO model. As expected, antibody treatment
resulted in reduction in levels of phosphorylated Smad3 in the
WAT of Lepob/ob and DIOmice (Figure 7A). Compared to animals
treated with the isotype control 13C4 antibody (IgG), administra-
tion of 1D11 antibody suppressed body weight gain (Figure 7B),
size of fat depots and fat mass (Figure S6A), adipocyte cell size
(data not shown), and levels of triglyceride (Figure S6B), resistin,
and leptin (data not shown). Moreover, we observed significantly
reduced inflammatory F4/80+ cells (Figure S6C) and inflamma-
tory cytokine levels, accompanied by a switch in the M1 to M2
macrophage spectrum in the WAT of antibody-treated mice
(data not shown). Also consistent with the data on Smad3/
mice, WAT from mice treated with 1D11 showed significant
increases in mitochondrial DNA copy number (Figures S3B and
S3C) and in transcripts that regulate BAT, mitochondrial func-
tion, and skeletal muscle biology (Figures 5A, 5B, S6E, andS6F and Table S3). Importantly, treatment with 1D11 improved
glucose and insulin tolerance (Figures 7C, 7D, and S6D), sup-
pressed hyperglycemia and hyperinsulinemia (Figures 7E and
7F), ameliorated hepatic steatosis (Figure 7G), and increased
protein levels of BAT/mitochondrial markers in the WAT
(Figure 7H).
DISCUSSION
Food intake in excess of metabolic needs results in continued
energy storage, thereby promoting obesity and diabetes.
Discovering approaches to either prevent fat storage or promote
fat dissipation could have a major clinical impact. A potentially
powerful approach to burn excess fat is to activate a program
of thermogenesis by tissues such as the skeletal muscle and
BAT that contain abundant mitochondria. Brown fat and skeletal
muscle share developmental origins (Seale et al., 2008), and
metabolically active BAT stores exist in humans (Nedergaard
et al., 2007), opening new therapeutic avenues for obesity and
diabetes (Enerba¨ck, 2010; Nedergaard and Cannon, 2010).
There are a preponderance of data supporting the existence of
brown adipocytes within the WAT milieu, although the signaling
pathways that regulate the appearance of these brown
adipocytes is largely obscure. Our data suggest that the
TGF-b/Smad3 pathway is an important determinant of this
phenomenon. In particular, we show that suppression ofCell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc. 75
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tolerance and an overall enhanced metabolic profile. The overall
effects of Smad3 deletion reported here may not be singularly
attributed to changes observed in the WAT, and it is plausible
that the contribution of other organs may influence the overall
phenotype. Additionally, we have previously showed that
Smad3 deletion results in an improved pancreatic islet b cell
function (Lin et al., 2009a). We do not detect increased glucose
uptake in gastrocnemius muscle, which has a high percentage
of white glycolytic fibers, although glucose uptake was not
normalized for fiber type. Also, we did not evaluate muscle mito-
chondrial measures such as mtDNA or citrate synthase activity
as such studies, although important, are out of the scope of
this manuscript.
The majority of the studies described here were performed
using the Smad3-deficient mice maintained on a mixed 129Sv/
C57BL/6 genetic background that have a variable susceptibility
to amild immune dysfunction (Yang et al., 1999). To investigate if
genetic background influences the phenotypes described here,
we backcrossed the 129Sv/C57BL/6-Smad3mutantmice (Datto
et al., 1999) for ten generations into a pure Balb/C genetic back-
ground. Similar to what was observed in 129Sv/C57BL/6-
Smad3/ mice, Balb/C-Smad3/ mice exhibited reduced fat
mass, lower fasting- and fed-glucose levels, improved glucose
and insulin tolerance (Figures S7A–S7F), alterations in thermo-
regulation (Figures S7G and S7H), and elevated transcript and
protein levels of BAT/mitochondrial markers (Figure S7I and
Table S5).
As expected, the degree of BAT-specific marker expression is
comparatively higher in BAT versus that seen in WAT. However,
we find that loss of Smad3 does not lead to increased intrascap-
ular BAT functionality per se under basal conditions or in
response to cold exposure. Consistent with this, Smad3/
MEFs differentiate toward the brown adipocytic lineage in
a manner equivalent to that observed in Smad3+/+ MEFs, and
macro and microscopic BAT is similar in morphological appear-
ance to that observed in Smad3+/+ mice (data not shown).
However, we cannot eliminate the possibility that intrascapular
BAT functionality contributes to the overall metabolic pheno-
type. Further, the protective effects of Smad3 deletion or
anti-TGF-b antibody treatment could be due to a change in the
infiltrating macrophage spectrum, although it is unclear whether
this is a cause or a consequence of the adiposity. Increased
metabolism could also be due to an insulation phenotype, as
seen in the SCD1/ mouse (Cannon and Nedergaard, 2011;
Sampath et al., 2009). However, levels of UCP1 under basal
conditions are similar in BAT from Smad3+/+ and Smad3/
mice. Further, the fur in Smad3/ mice appears normal and,
in contrast to SCD1/mice, the Smad3/mice do not display
cold intolerance. Thus, we infer that Smad3/ mice do not
exhibit an insulation phenomenon.
Smad3/micewere able tomaintain significantly higher body
temperature, even when exposed to cold for an extended time.
Since the Smad3/ mice are global knockouts, there could be
a major effect on body temperature ‘‘set-point’’ in the hypothal-
amus. Technical limitations preclude us from performing simul-
taneous and continuous body temperature and metabolic rate
measurement studies onmice administered anti-TGF-b antibody
treatment. Thus, we are unable to dissociate the central and76 Cell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc.peripheral actions of TGF-b/Smad3 signals on metabolic param-
eters. It is plausible that the overall phenotype we describe here
represents a complex phenomenon, where the absence of
Smad3 has an independent central effect on body temperature
with the associated metabolic increases and further has distinct
effects peripherally on the phenotype of the cells developing in
the WAT. Further, there may also be an increased sympathetic
drive to defend the increased body temperature, which could
contribute by activating the brown (and brown-like) adipocytes.
We plan to dissociate the central versus peripheral actions of
TGF-b/Smad3 using conditional tissue-specific knockout mice.
We suggest that the leanness and beneficial glucose homeo-
stasis are due, at least in part, to the elevated energy expenditure
as a consequence of an increased mitochondrial activity in the
WAT. Increased mitochondrial uncoupling can result in a benefi-
cial metabolic phenotype, and mouse models demonstrating
increased UCP1 expression inWAT are resistant to diet-induced
obesity (Narvaez et al., 2009; Polak et al., 2008). Given the
increase in ATP levels (Figure 4C), we infer that the basis for
increased basal oxygen consumption upon Smad3 deletion is
most likely due to the increased number of mitochondria and
that uncoupling is not likely to play a major role in the basal un-
stimulated state. Nonetheless, our data demonstrating that in
shSmad3 expressing cells, adrenergic stimulation can augment
respiration (Figure 4G) suggest the existence of an inducible un-
couplingmachinery. We suggest that the ability of TGF-b/Smad3
to modulate the overall lean phenotype is mediated by Smad3-
regulating PGC-1a, which in turn controls the induction of mito-
chondrial biogenesis and UCP1 gene expression. Reactive
oxygen species (ROS) are implicated in insulin resistance, and
under certain experimental paradigms, we could detect differ-
ences in the level of ROS produced fromWAT mitochondria iso-
lated from Smad3+/+ and Smad3/ mice (Figure S4C). The
precise meaning of these differences will require further
experimentation.
Treatment of WAT with the PPARg agonist rosiglitazone
promotes norepinephrine-augmentable UCP1 gene expression
in a subset of white adipocyte cells (Petrovic et al., 2010).
Although these cells exhibit thermogenic capacity, unlike the
cells we describe here, they do not express BAT/muscle-specific
markers. Strikingly, global microarray analyses of the WAT, from
Smad3/ mice and mice treated with 1D11 antibody, show
evidence of a unique signature of 103 genes, the majority
(60%) of which are involved in BAT, mitochondrial biology,
and skeletal muscle development and function, a finding that is
consistent with the nexus between brown fat and skeletal
muscle (Seale et al., 2008). It is possible that a small pool of
brown adipocyte precursors or a shared WAT/BAT/skeletal
muscle progenitor may reside in the white fat environment.
Thus, it is plausible that the TGF-b1 effect could be at the level
of the common progenitor for white, brown, and muscle cells,
and we are examining this possibility. Interestingly, TGF-b family
members regulate differentiation either into adipocytes or
myocytes in left atrium-derived pluripotent cells (Kawaguchi
et al., 2010), thus further supporting the possibility of TGF-b’s
role in modulating the adipocyte and BAT/muscle phenotypic
switch. Further, the TGF-b superfamily member, BMP7, is also
implicated in brown adipogenesis (Tseng et al., 2008). We
observed similar phosphorylation levels of the BMP-specific
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3T3-L1 cells with BMP7 did not alter Smad3 phosphorylation
(data not shown). Furthermore, the expression level of myostatin
(McPherron and Lee, 2002), the TGF-b superfamily member
implicated in muscle development and insulin sensitivity, and
its target gene dDahl was similar in Smad3+/+ and Smad3/
WAT (data not shown). These results do not suggest a major
role for BMP7 or myostatin in the observed Smad3-regulated
WAT-to-BAT phenotype. TGF-b regulates adipocyte differentia-
tion via a Smad3-C/EBP interaction (Choy and Derynck, 2003;
Choy et al., 2000), and Schnurri-2 interacts with Smads and
C/EBP during BMP2-regulated adipogenesis (Jin et al., 2006).
Our observations of active TGF-b1 (colocalized with perilipin)
and phosphorylated Smad3 in the WAT from DIO and Lepob/ob
mice suggests that TGF-b1 is produced in white adipocytes
during conditions of adiposity or glucose intolerance, although
this does not eliminate the stromal vascular fraction as a source
of TGF-b1 (Fain et al., 2005). These studies, altogether, suggest
an important role for TGF-b superfamily members in WAT and
BAT biology, akin to the role of myostatin in muscle development
(McPherron and Lee, 2002).
Intriguingly, the majority of TGF-b1 in the liver and heart is
located in mitochondria, as determined by electron microscopy
and cell fractionation studies (Heine et al., 1991). Our data are
consistent with a potential role for TGF-b in mitochondrial func-
tion within the adipocyte with regard to energy homeostasis.
Further, the recently described role for TGF-b in glucose-
induced cell hypertrophy (Wu and Derynck, 2009) may have
ramifications in conditions associated with hyperglycemia,
glucose intolerance, and insulin resistance. Circulating TGF-b
levels are elevated in cardiovascular disease and hypertension
(Gordon and Blobe, 2008), and TGF-b1 and BMI are closely
associated in human adipose tissue during morbid obesity
(Alessi et al., 2000). Elevated TGF-b1 levels in humans correlate
positively with increased adiposity and poor metabolic profile
(Figure 6A) and inversely correlate with fitness, as evidenced
by reduced oxygen consumption (VO2 max) during maximal
exercise testing (Figure S5A). Predisposition to various forms
of cancer, atherosclerosis, myocardial infarction, hypertension,
and stroke is correlated with the presence of TGF-b1 polymor-
phisms (Grainger et al., 1999). Further, polymorphisms such as
the T29C polymorphism, which results in a Leu-Pro substitution
at codon 10, are correlated with elevated circulating TGF-b
levels. Interestingly, the T29C polymorphism is associated with
increased BMI, elevated fasting insulin and glucose levels, and
higher HOMA insulin resistance indices (Rosmond et al., 2003).
Moreover, the SMAD3 gene was identified in a type 2 diabetes
genome-wide association study (Perry et al., 2009), which further
supports the notion of TGF-b/Smad3 pathway as a potential
target in diabetes and obesity. TGF-b antagonist approaches
are being clinically evaluated to treat diseases such as cancer,
fibrosis, scarring, and diabetic nephropathy where elevated
TGF-b levels are implicated. The occurrence of elevated
TGF-b1 levels in obese individuals combined with the beneficial
effect of the anti-TGF-b neutralization antibody in mouse models
of obesity and diabetes offer treatment alternatives for these
diseases. In conclusion, these results offer insight into the role
of TGF-b in adipose tissue biology, specifically with regard to
activation of a brown adipocyte program within white fat, anda strong potential for translation of these observations for the
treatment of obesity and diabetes.
EXPERIMENTAL PROCEDURES
Mice
The generation of Smad3/mice has been described previously (Datto et al.,
1999; Yang et al., 1999). C57BL/6J and Lepob/ob mice were intraperitoneally
injected with 1.5 mg/kg body weight of control 13C4 antibody or anti-TGF-b
antibody (1D11). All animal studies were approved by the NIDDK/NIH Animal
Care and Use Committee.
Indirect Calorimetry
Three-month-old female mice were studied in an eight-chamber Oxymax
system. Motor activity was determined by infrared beam interruption. Experi-
ments were performed at 20C and 30C.
Euglycemic-Hyperinsulinemic Clamp and Body Composition
Measurements
Insulin-stimulated whole-body glucose flux was estimated using a continuous
infusion of high-pressure liquid chromatography-purified [3-3H]glucose
(0.1 mCi/min). Blood samples were taken for determination of plasma [3H]
glucose, 2-deoxy-D-[1-14C]glucose, and 3H2O concentrations. WAT glucose
uptake was calculated from the plasma 2-deoxy-D-[1-14C]glucose concentra-
tion. Body composition was measured in nonanesthetized mice using Echo
3-in-1 NMR analyzer.
Glucose and Insulin Tolerance Tests
For glucose tolerance tests, overnight-fasted mice were given i.p. glucose
(2 mg/g body weight). For insulin tolerance test, fedmice were given i.p. insulin
(Humulin).
Mitochondrial Isolation and Intact Cell Metabolic Studies
Mitochondrial respiration was measured in a Model 210 fiber optic oxygen
monitor. Pyruvate and malate (5 mM/2 mM) were used as substrates, and
ADP (0.85 mM), oligomycin (0.125 mM), and atractyloside potassium salt
(0.5 mM) were added to evaluate mitochondrial coupling. Respiratory control
ratio was calculated as the ratio of oxygen consumption rate after (state 3) and
before (state 4) ADP addition.
Luciferase Reporter Assay
We transfected 23 105 cells/well with 1 mg/well of PGC1-a promoter reporter,
together with 0.1 mg/well of Renilla-luc plasmid, using FuGENE 6 transfection
reagent. Cells were treated with TGF-b, and luciferase activity was estimated
using Promega dual luciferase assay kit.
ChIP Assay
ChIP assay was performed using the ChIP-IT kit from Active Motif by following
the manufacturer’s instructions.
Human Study Subject Population
Study 1: The subjects were participants in the Triglyceride and Cardiovascular
Risk in African Americans study. Study 2: Subjects were enrolled to phenotype
varying degrees of obesity. The protocols were approved by the institutional
review board of NIDDK.
Statistical Analysis
For mouse studies, data are expressed as mean ± SEM. Statistical signifi-
cance between groups was determined using two-tailed Student’s t test or
one-way ANOVA. For human study analyses, a log transform was used for
TGF-b1. The results were presented as mean ± SD or SEM. Pearson’s corre-
lation analysis was performed between TGF-b1 and other variables. A p value
of <0.05 was considered statistically significant, and all tests were two sided.
Statistical analyses were performed using SAS version 9.1 (SAS Institute,
Cary, NC).Cell Metabolism 14, 67–79, July 6, 2011 ª2011 Elsevier Inc. 77
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Microarray analyses were performed using standard procedures. The data set
has been deposited in the GEO public database (accession #GSE28598).
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